🚨🚨🚨 Rectal Cancer Tweetorial!! Rectal cancer is a highly heterogeneous disease with rapid evolution in practice. Let's review current data to generate a pragmatic, patient-centric, approach to management! #GI24 #GIonc #RadOnc Thank you ASCO for the opportunity!🙏🏽 1/

TACE vs. SBRT for HCC TACE 🚫 📈 G3+ Toxicity. 🚫 Less cost-effective than RT, even if compared to carbon ions! 🚫 Invasive. 🚫Total ablation = the exception. 🚫LC ~40-50%. SBRT ✅📉 G3+ Toxicity. ✅More cost-effective. ✅Non-invasive. ✅Total ablation = the rule. ✅ LC ~85%.

🚨🚨🚨 Secondary analysis of GOG 258 suggests p53 status may be predictive (Yes! Not just prognostic) of response for advanced endometrial cancer p53 WT associated with improved RFS when treated with chemotherapy + RT vs chemo alone. NRG Oncology

18th ZAP-X of the World ! #zapx #meditrion Melek Tugce Yilmaz MD Hacettepe Üniversitesi Ecem Yigit

So grateful to host Prof. Sean Collins Prostate SBRT @ USF Health in Turkey and to learn a lot from him! Huge thanks 🙏🏻

A never ending story ➡️ Central 🫁 SBRT EORTC LungTech Trial (8x7.5 Gy) ❗️Severe late toxicity: 19.4% ❗️ ~ 3x higher than the SUNSET by David Palma, MD, PhD What are the main differences between these trials and how can we improve the safety profile of SBRT? jto.org/article/S1556-…

Our recent study, which revealed that a cisplatin dose of >200 mg improved survival in cervical cancer patients receiving CRT, has been published.OncoAlert Hasan Çağrı Yıldırım pubmed.ncbi.nlm.nih.gov/38950923/

#EditorsChoice Notable surgical trials in gynecologic oncology: a 10-year overview 🔍 bit.ly/3X9Yf7h Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes IGCS ESGO European Network of Young Gynae Oncologists OncoAlert IJGC Fellows SoMe4GynOnc Clarita Santía René Pareja

Diagnosis and Treatment of Radiation Induced Pneumonitis in Patients with #LungCancer, an ESTRO clinical practice #guideline just published in the Radiotherapy & Oncology 👉 thegreenjournal.com/article/S0167-… #radonc

⚡️ New multicenter data on SBRT for primary renal cell carcinoma (RCC): - 98% LC at 1 year, 96% at 5 years - Median OS: 58 months - Preserved renal function & low severe toxicity A promising noninvasive option for inoperable RCC #KidneyCancer #Oncology Shankar Siva

#ESTRO2025 was an amazing meeting with lots of impressive presentations, good science and great networking! Thank you ESTRO! Cem Önal Alison Tree 💙 prof. Barbara Jereczek-Fossa Alper Kahvecioglu MD Ecem Yigit

Honored to have our abstract on intravitreal melatonin for radiation retinopathy ranked among the top 5% at #ESTRO25 ! Proud of our team and grateful for the recognition 🙏🏻 Let’s keep advancing radiation oncology! ESTRO Ecem Yigit faruk zorlu

🚨 Just out in Red Journal! We analyzed our 191-patient H&N reirradiation cohort, with a specific focus on toxicity and CBOS 📊 Real-world SBRT data 🧑‍⚕️ Lessons on patient selection & risk mitigation redjournal.org/article/S0360-… IJROBP - The Red Journal Gozde Yazici Alper Kahvecioglu MD Ecem Yigit

Read a new #RedJournal article from Melek Tugce Yilmaz MD et al on 15 Years of Experience with Stereotactic Body Radiotherapy for Recurrent Head and Neck Cancers: A Detailed Analysis of Patients with Carotid Blowout Syndrome. tinyurl.com/yilmazred

Check out the SUNSET dosimetry study in IJROBP - The Red Journal. Key findings: - 73% treated without PTV compromise - PTV compromise not associated with local control - More overlap with central structures worse local control - Remember: IV contrast + 4D CT required, 5 mm PTV margins,

New today in #PracticalRO: Joint guideline from ASTRO, ASCO & SSO on post-mastectomy radiation therapy for patients with breast cancer. Updated recommendations cover indications, dosing, fractionation & multidisciplinary techniques. #RadOnc #BreastCancer ow.ly/524k50WXGao

Hot off the press 📰 → Grog’s bimonthly newsletter has just been published! Catch up on the latest updates, insights, and highlights. #TROD #GROG #Newsletter